FR2708467B1 - Préparations d'immunoglobulines stabilisées et procédé pour leur préparation. - Google Patents

Préparations d'immunoglobulines stabilisées et procédé pour leur préparation.

Info

Publication number
FR2708467B1
FR2708467B1 FR9309416A FR9309416A FR2708467B1 FR 2708467 B1 FR2708467 B1 FR 2708467B1 FR 9309416 A FR9309416 A FR 9309416A FR 9309416 A FR9309416 A FR 9309416A FR 2708467 B1 FR2708467 B1 FR 2708467B1
Authority
FR
France
Prior art keywords
preparation
immunoglobulin preparations
stabilized immunoglobulin
stabilized
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9309416A
Other languages
English (en)
Other versions
FR2708467A1 (fr
Inventor
Grandgeorge Michel
Gattel Paule
Makula Marie-France
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Pasteur Merieux Serum et Vaccines SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Merieux Serum et Vaccines SA filed Critical Pasteur Merieux Serum et Vaccines SA
Priority to FR9309416A priority Critical patent/FR2708467B1/fr
Priority to CA 2167712 priority patent/CA2167712A1/fr
Priority to EP94923758A priority patent/EP0711176A1/fr
Priority to JP7505621A priority patent/JPH09500894A/ja
Priority to PCT/FR1994/000955 priority patent/WO1995003826A1/fr
Priority to AU73866/94A priority patent/AU7386694A/en
Publication of FR2708467A1 publication Critical patent/FR2708467A1/fr
Application granted granted Critical
Publication of FR2708467B1 publication Critical patent/FR2708467B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
FR9309416A 1993-07-30 1993-07-30 Préparations d'immunoglobulines stabilisées et procédé pour leur préparation. Expired - Fee Related FR2708467B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR9309416A FR2708467B1 (fr) 1993-07-30 1993-07-30 Préparations d'immunoglobulines stabilisées et procédé pour leur préparation.
CA 2167712 CA2167712A1 (fr) 1993-07-30 1994-07-28 Preparations d'immunoglobulines stabilisees et procedes pour leur preparation
EP94923758A EP0711176A1 (fr) 1993-07-30 1994-07-28 Preparations d'immunoglobulines stabilisees et procede pour leur preparation
JP7505621A JPH09500894A (ja) 1993-07-30 1994-07-28 安定化された免疫グロブリンの調製物と、その調製方法
PCT/FR1994/000955 WO1995003826A1 (fr) 1993-07-30 1994-07-28 Preparations d'immunoglobulines stabilisees et procede pour leur preparation
AU73866/94A AU7386694A (en) 1993-07-30 1994-07-28 Stabilised immunoglobulin preparations and method for preparing same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9309416A FR2708467B1 (fr) 1993-07-30 1993-07-30 Préparations d'immunoglobulines stabilisées et procédé pour leur préparation.

Publications (2)

Publication Number Publication Date
FR2708467A1 FR2708467A1 (fr) 1995-02-10
FR2708467B1 true FR2708467B1 (fr) 1995-10-20

Family

ID=9449802

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9309416A Expired - Fee Related FR2708467B1 (fr) 1993-07-30 1993-07-30 Préparations d'immunoglobulines stabilisées et procédé pour leur préparation.

Country Status (6)

Country Link
EP (1) EP0711176A1 (fr)
JP (1) JPH09500894A (fr)
AU (1) AU7386694A (fr)
CA (1) CA2167712A1 (fr)
FR (1) FR2708467B1 (fr)
WO (1) WO1995003826A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7651688B2 (en) 1999-04-09 2010-01-26 Kyowa Hakko Kirin Co., Ltd Method of modulating the activity of functional immune molecules to CD52
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
US7737325B2 (en) 2000-10-06 2010-06-15 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014148555A (ja) * 1995-07-27 2014-08-21 Genentech Inc タンパク質の処方
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU716785B2 (en) * 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
US6682746B2 (en) 1995-09-21 2004-01-27 Kristina J. Hennessy Adjuvanted vaccine which is substantially free of non-host albumin
CA2184132C (fr) 1995-09-21 2011-03-15 Kristina J. Hennessy Vaccin avec adjuvant, pratiquement exempt d'albumine non-hote
US6124437A (en) * 1997-03-19 2000-09-26 Welfide Corporation Immunoglobulin preparation and preparation process thereof
EP0973549A2 (fr) 1997-04-07 2000-01-26 Cangene Corporation Composition intraveineuse d'immunoglobuline contenant un tensioactif non ionique aux proprietes pharmacocinetiques ameliorees
DE19830914C1 (de) * 1998-07-10 1999-06-24 Centeon Pharma Gmbh Verfahren zur Herstellung einer Proteinlösung
EP1475101B1 (fr) * 2002-02-14 2010-10-27 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
US8496930B2 (en) 2003-10-01 2013-07-30 Kyowa Hakko Kirin Co., Ltd Method of stabilizing antibody and stabilized solution-type antibody preparation
CA2681752A1 (fr) 2007-03-29 2008-10-09 Abbott Laboratories Anticorps anti-1l-12 humains cristallins
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
FR2961107B1 (fr) * 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
TWI750108B (zh) 2014-04-03 2021-12-21 瑞士商Ｃｓｌ貝林股份有限公司 免疫球蛋白之霧化

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55164630A (en) * 1979-06-11 1980-12-22 Green Cross Corp:The Freeze-dried preparation of anti-hbs globulin
ES502788A0 (es) * 1981-06-04 1982-04-01 Landerlan Sa Lab Procedimiento de preparacion de imuno globulina g nativa li-bre de actividad anticomplementaria
DE68908175T2 (de) * 1988-05-27 1994-03-03 Centocor Inc Gefriergetrocknete formulierung für antikörperprodukte.
JPH0778025B2 (ja) * 1990-03-20 1995-08-23 日本赤十字社 免疫グロブリンｇの製造方法

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763246B2 (en) 1999-04-09 2010-07-27 Kyowa Hakko Kirin Co., Ltd. Method of modulating the activity of functional immune molecules to platelet-derived growth factor receptor
US7655228B2 (en) 1999-04-09 2010-02-02 Kyowa Hakko Kirin Co., Ltd Method of modulating the activity of functional immune molecules to GM2
US7682611B2 (en) 1999-04-09 2010-03-23 Kyowa Hakko Kirin Co., Ltd Method of modulating the activity of functional immune molecules to CXCR4 protein
US7682610B2 (en) 1999-04-09 2010-03-23 Kyowa Hakko Kirin Co., Ltd Method of modulating the activity of functional immune molecules
US7687061B2 (en) 1999-04-09 2010-03-30 Kyowa Hakko Kirin Co., Ltd Method of modulating the activity of functional immune molecules to Her-2
US8679491B2 (en) 1999-04-09 2014-03-25 Kyowa Hakko Kirin Co., Ltd. Method of modulating the activity of functional immune molecules
US7708997B2 (en) 1999-04-09 2010-05-04 Kyowa Hakko Kirin Co., Ltd Method of modulating the activity of functional immune molecules
US7708992B2 (en) 1999-04-09 2010-05-04 Kyowa Hakko Kirin Co., Ltd Methods for producing antibody compositions with increased ADCC
US7718175B2 (en) 1999-04-09 2010-05-18 Kyowa Hakko Kirin Co., Ltd Method of modulating the activity of functional immune molecules to interleukin-5 receptor protein
US7651688B2 (en) 1999-04-09 2010-01-26 Kyowa Hakko Kirin Co., Ltd Method of modulating the activity of functional immune molecules to CD52
US8101185B2 (en) 2000-10-06 2012-01-24 Kyowa Hakko Kirin Co., Ltd. Anti-il-5 antibody composition exhibiting cellular cytotoxicity due to glycosylation
US7741442B2 (en) 2000-10-06 2010-06-22 Kyowa Hakko Kirin Co., Ltd Antibody composition exhibiting increased cellular cytotoxicity due to glycosylation
US7846725B2 (en) 2000-10-06 2010-12-07 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell in which enzyme expression is inhibited by RNAi
US8039595B2 (en) 2000-10-06 2011-10-18 Kyowa Hakko Kirin Co., Ltd. Glycoengineered, recombinant antibody to CCR-4 with reduced fucosylation
US8067232B2 (en) 2000-10-06 2011-11-29 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell with inactivated A-1,6-fusocyltransferase
US7737325B2 (en) 2000-10-06 2010-06-15 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell
US8110195B2 (en) 2000-10-06 2012-02-07 Kyowa Hakko Kirin Co., Ltd. Antibody composition exhibiting cellular cytotoxicity due to glycosylation and containing ganglioside GM2 binding antibody
US8158760B2 (en) 2000-10-06 2012-04-17 Kyowa Hakko Kirin Co., Ltd Glycoengineered, recombinant antibody
US8329443B2 (en) 2000-10-06 2012-12-11 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell
US8367407B2 (en) 2000-10-06 2013-02-05 Kyowa Hakko Kirin Co., Ltd. Cells with altered fucosylation and producing antibodies therefrom
US8895266B2 (en) 2000-10-06 2014-11-25 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell
US9409982B2 (en) 2000-10-06 2016-08-09 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament

Also Published As

Publication number Publication date
WO1995003826A1 (fr) 1995-02-09
CA2167712A1 (fr) 1995-02-09
EP0711176A1 (fr) 1996-05-15
JPH09500894A (ja) 1997-01-28
AU7386694A (en) 1995-02-28
FR2708467A1 (fr) 1995-02-10

Similar Documents

Publication Publication Date Title
FR2708467B1 (fr) Préparations d'immunoglobulines stabilisées et procédé pour leur préparation.
IL99363A0 (en) Pharmaceutical compositions comprising homoconjugated monoclonal antibodies
DZ2420A1 (fr) Formulations nouvelles comprenant l'amoxycilline et du clavulanate et procédé pour leur préparation.
OA09387A (fr) "Procédé de préparation de compositions à libération prolongée et compositions ainsi obtenues".
DZ2370A1 (fr) Procédé de préparation d'hydrocarbures
OA08694A (fr) Acides 3-pyrrolidinylthio-1-azabicyclo [3.2.0] -hept-2-ène-2-carboxyliques et procédés pour leur préparation.
FR2707087B1 (fr) Nouveau procédé de préparation de l'ergothionéine.
FR2714848B1 (fr) Microcapsules et procédés pour leur préparation.
FR2698362B1 (fr) Calix [4] arènes-bis-couronnes, leur procédé de préparation et leur utilisation pour l'extraction sélective du césium et des actinides.
FR2698372B1 (fr) Procédé d'élimination de mercure et éventuellement d'arsenic dans des hydrocarbures.
FR2702660B1 (fr) Compositions thérapeutiques stabilisées et leur procédé de préparation.
HUT46062A (en) Process for producing human monoclonal antibody compositions protecting from bacterial infections and pharmaceutics comprising the same
FR2669321B1 (fr) Trichite d'apatite et methode pour sa preparation.
DZ2044A1 (fr) 5,6-Dihydro-9h-pyrazolo Ä3,4-cÜ-1,2,4-triazol Ä4,3-alphaÜpyridines tricycliques procédé pour leur préparation et compositions les contenant.
DZ1758A1 (fr) Procédé pour la préparation d'aryl-piperidine carbinols.
HU906302D0 (en) Process for producing 3'azido-purine-nucleosides and pharmaceutical preparatives containing these compounds
FR2720070B1 (fr) Procédé de préparation d'alkylpolysiloxanes pontés et alkylpolysiloxanes pontés.
FR2721598B1 (fr) Procédé de préparation de catalyseurs d'ammoxydation.
FR2708266B1 (fr) Procédé de préparation d'alcanesulfonamides.
FR2715656B1 (fr) Procédé de préparation d'anhydride citraconique.
FR2695645B1 (fr) Procédé de préparation de polyaminoborazines.
FR2630735B1 (fr) Procede de preparations d'halogenophenols
IL77990A (en) Monoclonal anti-alpha-amylase antibody,process for obtaining the same and pharmaceutical compositions containing the same
FR2701478B1 (fr) Dérivés de vitamine E contenant de l'azote quaternaire et procédés pour leur préparation.
FR2712511B1 (fr) Cartouche pour la préparation d'acides nucléiques purifiés.

Legal Events

Date Code Title Description
ST Notification of lapse